NCT07099742Not yet recruiting
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
A Study of Real-World Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) in Bangladesh
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in obese adults with or without Type 2 Diabetes Mellitus (T2DM). The study aims to determine whether treatment with Tirzepatide results in superior weight reduction outcomes compared to lifestyle-based approaches. Adult participants (≥18 years) with a body mass index (BMI) ≥25 kg/m² and no prior exposure to GLP-1 receptor agonists will be enrolled at the discretion of the treating physician. Eligible participants will receive either once-weekly Tirzepatide or participate in lifestyle intervention programs aligned with standard clinical care.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 364 (estimated)
- First submitted
- 25 Jul 2025
- Start date
- Nov 2026
- Primary completion date
- Oct 2027
- Lead sponsor
- Dr. Md. Alimur Reza
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07099742
What you commit to
- Study type: Observational
- Planned participants: 364
- From Nov 2026 to the primary completion date, Oct 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior or planned surgical treatment for obesity.
- Use of weight-loss products (including prescription medications, over-the-counter drugs, or herbal preparations) within 3 months prior to screening.
Other illness
- Diagnosis of diabetes other than Type 2 Diabetes Mellitus.
- History of chronic or acute pancreatitis.
- Presence of acute medical conditions, including acute hepatitis, myocardial infarction, stroke, heart failure, febrile illness, or acute diarrheal disease.
- Evidence of significant, uncontrolled endocrine disorders (e.g., Cushing's syndrome, thyroid disorders, adrenal insufficiency, congenital adrenal hyperplasia).
- History or presence of malignancy.
- Active gallbladder disease.
Other
- Female participants who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential, not using adequate contraceptive methods.
Who the study is looking for
- Adult patients of both sexes, aged ≥18 years.
- Body mass index (BMI) ≥25 kg/m².
- Naïve to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.
- Self-reported stable body weight (change ≤5 kg) over the past 3 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Trauma Centre, Cumilla. Coordinator of this site? Confirm its status | Comilla | Bangladesh | Unknown status |
| Dhaka Medical College Hospital, Dhaka Coordinator of this site? Confirm its status | Dhaka | Bangladesh | Unknown status |
| Rajshahi Medical College Hospital, Rajshahi Coordinator of this site? Confirm its status | Rajshahi | Bangladesh | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.